1. Catalog
  2. Hepatoxicity SIG (Jan 15) GLP-1 receptor agonists ...
Hepatoxicity SIG (Jan 15) GLP-1 receptor agonists and Hepatotoxicity
Create Account
Availability
On-Demand
Cost
Member: $0.00
Non-Member: $25.00
Patient: $0.00
Associate: $15.00
Student: $0.00
Early Career: $0.00
Industry Rep: $25.00
Credit Offered
No Credit Offered
  • Description
  • Faculty
  • Privacy Policy
  • Recommended
Semaglutide was the first GLP-1 receptor agonist (GLP-1RA) to be approved for MASH with fibrosis. Other GLP-1RAs are in advanced development for MASH, with many also in development for weight reduction in adults with obesity. In addition, GLP-1RA have been widely used in patients with type 2 diabetes mellitus (T2DM) for many years. Recently, two oral GLP-1RAs - Danuglipron (Pfizer) and TERN-601 were linked to suspected hepatotoxicity leading to halting of further clinical development of these agents. This presentation will cover the liver safety of GLP-1 RA's.

COPYRIGHT: All faculty in this activity have given their permission for publication ©2026 AASLD.

This activity will not offer CE Credit.
Melissa Palmer, MD, FAASLD
Powered By